Literature DB >> 34343532

The association between late-phase early recurrence within the blanking period after atrial fibrillation catheter ablation and long-term recurrence: Insights from a large-scale multicenter study.

Naoaki Onishi1, Kazuaki Kaitani2, Yoshihisa Nakagawa3, Koichi Inoue4, Atsushi Kobori5, Yuko Nakazawa6, Tomoya Ozawa6, Toshiya Kurotobi7, Itsuro Morishima8, Fumiharu Miura9, Tetsuya Watanabe10, Masaharu Masuda11, Masaki Naito12, Hajime Fujimoto13, Taku Nishida14, Yoshio Furukawa15, Takeshi Shirayama16, Mariko Tanaka17, Katsunori Okajima18, Takenori Yao19, Yasuyuki Egami20, Kazuhiro Satomi21, Takashi Noda22, Koji Miyamoto22, Tetsuya Haruna23, Yukei Higashi24, Makoto Ito25, Minoru Horie6, Kengo F Kusano22, Wataru Shimizu26, Shiro Kamakura27, Yukiko Shimizu28, Koji Hanazawa29, Toshihiro Tamura30, Chisato Izumi31, Takeshi Morimoto32, Takeshi Kimura33, Satoshi Shizuta33.   

Abstract

BACKGROUND: The relationship between the timing of the first early recurrence and late recurrence after a single catheter ablation procedure for atrial fibrillation is controversial.
METHODS: The Efficacy of Short-Term Use of Antiarrhythmic Drugs After Catheter Ablation for Atrial Fibrillation trial followed 2038 patients who underwent radiofrequency catheter ablation for atrial fibrillation.
RESULTS: Of the patients, 907 (45%) had early recurrences within 90 days after the initial ablation. We divided these patients into two groups according to the timing of the first early recurrence episode, namely the ER1 group (early recurrence during the early phase; 0-30 days, n = 814) and ER2 group (early recurrence during the late phase; 31-90 days, n = 93). Three years after ablation, patients with early recurrences had a significantly lower event-free rate from late recurrences after a 90-day blanking period than patients without early recurrences (36.2% and 74.2%, respectively; log-rank, P < 0.0001). Three years after ablation, the event-free rate was significantly higher in the ER1 than the ER2 group (38.3% and 17.1%, respectively; log-rank, P < 0.0001). Moreover, the event-free rate at 3 years in the ER2 group was extremely low (5.6%) in patient with non-paroxysmal atrial fibrillation.
CONCLUSION: Early recurrences were strongly associated with late recurrences, especially in patients with the first recurrence episode at >1 month within the blanking period after a single ablation procedure. Therefore, these patients should undergo close observation during follow-up, when they had especially with non-paroxysmal atrial fibrillation.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Atrial fibrillation; Blanking period; Early recurrence; Late recurrence; Radiofrequency catheter ablation

Year:  2021        PMID: 34343532     DOI: 10.1016/j.ijcard.2021.07.053

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Localized Myocardial Anti-Inflammatory Effects of Temperature-Sensitive Budesonide Nanoparticles during Radiofrequency Catheter Ablation.

Authors:  Ye Liu; Lingling Xu; Qiuyun Zhang; Yong Kang; Lifeng Liu; Zheng Liu; Yuxing Wang; Xuejiao Jiang; Yizhu Shan; Ruizeng Luo; Xi Cui; Yuan Yang; Xinchun Yang; Xiaoqing Liu; Zhou Li
Journal:  Research (Wash D C)       Date:  2022-05-31

2.  Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study.

Authors:  Filippo Cacioppo; Michael Schwameis; Nikola Schuetz; Julia Oppenauer; Sebastian Schnaubelt; Alexander Simon; Martin Lutnik; Sophie Gupta; Dominik Roth; Harald Herkner; Alexander Oskar Spiel; Anton Norbert Laggner; Hans Domanovits; Jan Niederdoeckl
Journal:  Int J Environ Res Public Health       Date:  2022-05-28       Impact factor: 4.614

3.  Impact of atrial fibrillation ablation on long-term outcomes in patients with tachycardia-bradycardia syndrome.

Authors:  Shohei Kataoka; Koichiro Ejima; Kyoichiro Yazaki; Miwa Kanai; Daigo Yagishita; Morio Shoda; Nobuhisa Hagiwara
Journal:  J Arrhythm       Date:  2022-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.